Companies Dominating the Oral Immunostimulant Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Step-Pharma
- Abbott
- Biogen
- Novartis AG
- Amgen
- Merck & Co.
- Johnson & Johnson
- Eli Lilly and Company
- Bristol-Myers Squibb Company
Browse Key Market Insights with Data Illustration:
In the News
- Abbott announced that Abbott HeartMates Programs which is a new initiative that will kick off with professional football player Damar Hamlin as its first ambassador. Moreover, Abbott has invited people who are committed to inspiring others through their heart-healthy stories to join Hamlin in the HeathMates team. The team is comprised of people who are affected by health conditions including cardiovascular patients, caregivers, family, and friends. The team will collaborate directly with Abbott and Hamlin as a program ambassador and promote HeartMates community-building tenets to those impacted by heart conditions.
- Step Pharma announced that pre-clinical data on its first-in-class, highly selective, orally bioavailable CTPS1 inhibitor, were presented at the 64th American Society for Hematology Annual Meeting held from 10-13 December 2022 in New Orleans virtually. Moreover, the data presented by Step Pharma collaborators demonstrates the potential of STP938, a highly selective CTPS1 inhibitor, as a therapeutic for the treatment of mantle cell lymphoma and multiple myeloma both as a single agent and in combination with other targeted inhibitors. Moreover, single agent STP938 also showed activity in preclinical models of multiple myeloma and demonstrated strong synergy when combined with an inhibitor of DNA in the damage response pathway.
